DexCom's accelerating revenue growth (13.1% YoY in 2026Q2) and robust gross margin expansion to 63.4% underscore strong operational execution, driven by expanded CMS coverage and pharmacy channel adoption. The company has significantly deleveraged, cutting tot...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.1% YoY in 2026Q2, with gross margin expanding to 63.4% and operating margin reaching 24.3%, reflecting strong operating leverage and disciplined R&D spending.
Dexcom has set the standard in glucose biosensing for 25 years, with best-in-class technologies and continuous product innovation.
The company is expanding its market reach into Type 2 diabetes, driving user growth and broadening its customer base.
Dexcom has significant institutional backing, with top holder Vanguard Group owning 11% of the company, indicating strong investor confidence.
Trailing total returns as of 10/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.70+14.6% vs $0.61 | $1.3B+1.4% vs $1.3B |
Q2 2026 Apr 30, 2026 | $0.56+20.3% vs $0.47 | $1.2B+1.5% vs $1.2B |
Q1 2026 Feb 12, 2026 | $0.68+4.6% vs $0.65 | $1.3B+0.9% vs $1.2B |
Q4 2025 Oct 30, 2025 | $0.61+5.9% vs $0.58 | $1.2B+2.2% vs $1.2B |
[url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of [url="]Dexcom U[/url], the
SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program's largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Benchmark DXCM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DexCom, Inc. (DXCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $83.39 | $32.18B | 39.90 | 15.6% | 17.94% | 34.5% | — | |
| $98.17 | $170.99B | 26.39 | 5.67% | 13.91% | 12.09% | — | |
| $134.73 | $9.33B | 38.72 | 30.73% | 12.29% | 26.69% | — | |
| $16.16 | $1.11B | -5.32 | 7.93% | -6.08% | -45.97% | — | |
| $14.97 | $1.73B | -12.27 | 8.28% | -21.25% | -44% | — | |
| $20.83 | $1.54B | 6.31 | 18.52% | 80.56% | 30.03% | — |
DexCom, Inc. (DXCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DexCom, Inc. (DXCM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 28, 2026·SEC
May 15, 2026·SEC
Get notified when DXCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DexCom, Inc. (DXCM) stock FAQ — growth, dividends, profitability & financials explained
DexCom, Inc. (DXCM) reported $4.97B in revenue for fiscal year 2025.
DexCom, Inc. (DXCM) grew revenue by 15.6% over the past year. This is strong growth.
Yes, DexCom, Inc. (DXCM) is profitable, generating $999.7M in net income for fiscal year 2025 (17.9% net margin).
DexCom, Inc. (DXCM) has a return on equity (ROE) of 34.5%. This is excellent, indicating efficient use of shareholder capital.
DexCom, Inc. (DXCM) generated $1.41B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
